Health

 
  • 4 Week Diet Program By Brian Flatt Allows You To Lose 20 Pounds With The 4 Week Diet System

    4 Week Diet Program By Brian Flatt Allows You To Lose 20 Pounds With The 4 Week Diet System

    BOISE, Idaho, April 21, 2018 (GLOBE NEWSWIRE) — Brian Flatt became well known on the International scene after his books  and  dietary  systems  were  proven  by  their  results  to  be  highly  successful  with  all  body types. He has completed a massive amount of research and has launched the one diet plan in the  world  that  can,  and  does,  have  the  […]

     
     
  • How To Lose Weight Fast With Brian Flatt‘s New 2 Week Weight Loss Program

    How To Lose Weight Fast With Brian Flatt‘s New 2 Week Weight Loss Program

    SAN DIEGO, April 22, 2018 (GLOBE NEWSWIRE) — Brian Flatt creator of The 2 Week Diet explains why dieters dissatisfied with ineffective, run-of-the-mill diets now have access to a groundbreaking program that guarantees weight loss of 8-16 pounds in 14 days. Brian Flatt, a seasoned nutritionist and owner of R.E.V. Fitness, developed The 2 Week Diet in response to “mainstream […]

     
     
  • Sensorion and Uconn Health Announce Identification of First Potential Biomarker for Noise-Induced Hearing Loss

    Sensorion and Uconn Health Announce Identification of First Potential Biomarker for Noise-Induced Hearing Loss

    New study shows prestin in the blood following noise-induced trauma may be a biomarker for hearing loss MONTPELLIER, France, April 23, 2018 (GLOBE NEWSWIRE) — New preclinical study findings presented at the 53rd American Neurotology Society (ANS) Annual Spring Meeting reveal the first potential biomarker for noise-induced hearing loss. The collaborative research study’s findings were jointly presented by Sensorion (FR […]

     
     
  • Catalyst Pharmaceuticals Announces Enrollment of First Patient in Phase 3 Trial of Firdapse® in MuSK Antibody Positive Myasthenia Gravis

    Catalyst Pharmaceuticals Announces Enrollment of First Patient in Phase 3 Trial of Firdapse® in MuSK Antibody Positive Myasthenia Gravis

    CORAL GABLES, Fla., April 19, 2018 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that the first patient has been enrolled into its Phase 3 clinical trial (designated as MSK-002) to evaluate the efficacy and safety of Firdapse® […]

     
     
  • New Novartis analyses at AAN show siponimod‘s efficacy on disability and cognition in secondary progressive MS patients

    Basel, April 20, 2018 – Novartis today announced new analyses from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in patients with secondary progressive multiple sclerosis (SPMS). In pre-specified statistical analyses, treatment with siponimod consistently reduced the risk of confirmed disability progression in SPMS patients, with and without relapses[1]. In addition, new post-hoc analyses using more accurate methods […]